AOD-9604

What is AOD-9604?

AOD-9604 is a synthetic peptide derived from the last 16 amino acids of human growth hormone (hGH) — the region near the C-terminus, residues 176–191, with a small structural modification. This fragment corresponds to the part of the growth-hormone molecule that researchers identified as responsible for its fat-burning (lipolytic) activity.

The idea behind AOD-9604 is to isolate that fat-metabolism effect while leaving behind the parts of growth hormone that drive tissue growth, raise IGF-1, and affect blood sugar. It was originally developed as an anti-obesity candidate. It is not an FDA-approved drug; in the United States it is available only as a pharmacy-compounded preparation prescribed under physician supervision.

How AOD-9604 works

AOD-9604 is thought to act on fat (adipose) tissue much the way the C-terminal region of intact growth hormone does — stimulating lipolysis, the breakdown of stored triglycerides, and inhibiting lipogenesis, the formation of new fat. Animal work has linked this activity to β3-adrenergic receptor signaling in fat cells.

Critically, in preclinical models AOD-9604 produced these metabolic effects without binding the growth-hormone receptor in a way that raises IGF-1 or impairs glucose tolerance. That separation — fat metabolism without the growth and insulin-related actions of full hGH — is the central rationale for the molecule. Whether it translates into meaningful clinical fat loss in people is a separate question the human data have not clearly answered.

What AOD-9604 is used for

What the evidence shows

In laboratory and animal studies, AOD-9604 has repeatedly shown lipolytic activity — increasing fat breakdown and reducing fat accumulation — while, unlike full growth hormone, not raising IGF-1 or disturbing blood-glucose control in those models [1][2].

The human evidence is where candor matters most. AOD-9604 advanced into clinical trials as an oral anti-obesity candidate, and early-phase results were encouraging enough to justify a larger program. But the pivotal human weight-loss studies were disappointing: the effect on body weight was modest and, in the key trials, did not separate convincingly from placebo. The molecule was not brought to market as an obesity drug on the strength of those results [3].

So the honest summary is this: AOD-9604 has a clean mechanistic story and a reassuring safety record in humans, but it does not have robust clinical proof that it produces significant weight loss on its own. We share that plainly, because it should shape whether — and how — it fits your goals.

Dosing & administration context

AOD-9604 has been studied both orally and by subcutaneous injection; in clinical practice it is most often given as a daily subcutaneous injection, with the dose expressed in micrograms and courses measured in weeks to months.

The specific dose, route, frequency, and duration are individualized by the prescribing physician based on your goals, body composition, and response — which is why we frame this as clinical context, not a self-dosing guide. AOD-9604 obtained outside a licensed pharmacy (research-only vials, gray-market powders) carries no guarantee of identity, purity, or sterility.

AOD-9604 is not an FDA-approved medication. Content on this page is clinical context for physician-supervised, pharmacy-compounded use — not a dosing guide or a substitute for medical advice.

Safety & side effects

AOD-9604 has a favorable safety and tolerability profile in the human studies conducted to date, without the blood-sugar and growth-related concerns associated with full growth hormone. Reported side effects in clinical use are generally mild.

Because it is not an approved drug and long-term human data are limited, we screen carefully before prescribing and monitor throughout a course. As with every compounded peptide, source control is central — a product from a licensed 503A/503B pharmacy is a fundamentally different risk profile than a research vial of unknown origin.

How Strong Health prescribes AOD-9604

At Strong Health, AOD-9604 is prescribed only after a physician evaluation of your goals, metabolic health, and history. It is dispensed exclusively through licensed 503A or 503B compounding pharmacies under physician orders; we do not sell or recommend research-only product.

Given the mixed human efficacy data, we are deliberate about where AOD-9604 fits. We treat it as a possible adjunct within a comprehensive weight and metabolic plan — never a standalone fix — and we are transparent that better-validated options, including GLP-1 therapies, exist for weight loss. Your physician sets the protocol, reviews your response at scheduled intervals, and adjusts or stops treatment based on results.

Available in person at our Miami (Brickell) clinic and via telehealth across our service areas.

Frequently asked questions